Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities.

[1]  Sadiq S. Rehmani,et al.  Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities , 2021, PloS one.

[2]  P. D. De Leyn,et al.  Segmentectomy or lobectomy for early-stage non-small-cell lung cancer: a systematic review and meta-analysis. , 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  C. Kong,et al.  Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States , 2019, JAMA network open.

[4]  B. Meyers,et al.  Surgical Resection Versus Stereotactic Body Radiation Therapy for Stage I NSCLC: Can Randomized Trials Provide the Solution? , 2018, Cancers.

[5]  C. Henschke,et al.  Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/μl , 2018, AIDS.

[6]  L. Kazis,et al.  A new algorithm to build bridges between two patient-reported health outcome instruments: the MOS SF-36® and the VR-12 Health Survey , 2018, Quality of Life Research.

[7]  James D. Murphy,et al.  Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans. , 2018, The Annals of thoracic surgery.

[8]  D. Harpole,et al.  Improved Survival of Stage I Non‐Small Cell Lung Cancer: A VA Central Cancer Registry Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Wei Dong,et al.  Appropriate surgical modalities for stages T2a and T2b in the eighth TNM classification of lung cancer , 2017, Scientific Reports.

[10]  J. Dai,et al.  Segmentectomy versus wedge resection for the treatment of high-risk operable patients with stage I non-small cell lung cancer: a meta-analysis , 2016, Therapeutic advances in respiratory disease.

[11]  E. Yorke,et al.  Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. , 2016, International journal of radiation oncology, biology, physics.

[12]  W. Guan,et al.  Impact of COPD and emphysema on survival of patients with lung cancer: A meta‐analysis of observational studies , 2016, Respirology.

[13]  A. Neugut,et al.  Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: Impact of Histology. , 2015, Journal of Clinical Oncology.

[14]  K. Rosenzweig,et al.  Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Peter Balter,et al.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2015, The Lancet. Oncology.

[16]  M. Sonobe,et al.  Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. , 2015, The Annals of thoracic surgery.

[17]  E. Lim,et al.  Adjuvant or neoadjuvant chemotherapy for NSCLC. , 2014, Journal of thoracic disease.

[18]  A. Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.

[19]  D. Christiani,et al.  The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. , 2014, Chest.

[20]  Joe Y. Chang,et al.  Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? , 2013, Thoracic surgery clinics.

[21]  Alessandro Brunelli,et al.  Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[22]  A. Chang,et al.  Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[23]  G. Gazelle,et al.  Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer. , 2013, AJR. American journal of roentgenology.

[24]  D. Aberle,et al.  Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Christy Goldsmith,et al.  Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours , 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.

[26]  G Scott Gazelle,et al.  Chapter 9: The MGH‐HMS Lung Cancer Policy Model: Tobacco Control Versus Screening , 2012, Risk analysis : an official publication of the Society for Risk Analysis.

[27]  U. Sartipy,et al.  Predictors of Postoperative Quality of Life after Surgery for Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  P. Prorok,et al.  Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST) , 2011, Journal of medical screening.

[29]  P. Lambin,et al.  Health-related quality of life in patients surviving non-small cell lung cancer , 2010, Thorax.

[30]  J. Hanmer.  Predicting an SF-6D preference-based score using MCS and PCS scores from the SF-12 or SF-36. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  K. Sigel,et al.  Effect of Age on Survival of Clinical Stage I Non-Small-Cell Lung Cancer , 2009, Annals of Surgical Oncology.

[32]  P. Metcalf,et al.  COPD prevalence is increased in lung cancer, independent of age, sex and smoking history , 2009, European Respiratory Journal.

[33]  Taofeek K Owonikoko,et al.  Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Edward L Spitznagel,et al.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Simon,et al.  Predictors of enrollment in lung cancer clinical trials , 2006, Cancer.

[36]  M. Iannuzzi,et al.  Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. , 2005, Chest.

[37]  Robert C. Gooding,et al.  Enrollment of African Americans onto clinical treatment trials: study design barriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Gürsoy,et al.  Outcome of Surgery for Lung Cancer in Young and Elderly Patients , 2004, Surgery Today.

[39]  M. Lesperance,et al.  Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. , 2003, International journal of radiation oncology, biology, physics.

[40]  Ahmedin Jemal,et al.  Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden , 2002, Cancer.

[41]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[42]  J. Coebergh,et al.  Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. , 1999, Journal of clinical epidemiology.

[43]  J. Coebergh,et al.  Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. , 1998, Lung cancer.

[44]  H. Wada,et al.  Thirty-day operative mortality for thoracotomy in lung cancer. , 1998, The Journal of thoracic and cardiovascular surgery.

[45]  M. Mack,et al.  Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. , 1997, The Journal of thoracic and cardiovascular surgery.

[46]  L V Rubinstein,et al.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1995, The Annals of thoracic surgery.